STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - $MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: $MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co.'s position in the market.

News
Merck Announces Second-Quarter 2023 Financial Results
Rhea-AI Summary
Merck reports Q2 2023 financial results with total worldwide sales of $15.0 billion, an increase of 3% from Q2 2022. Key highlights include growth in KEYTRUDA and GARDASIL sales, decline in LAGEVRIO sales, and a GAAP loss per share of $2.35.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
earnings
-
News
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Rhea-AI Summary
Merck (MRK) announces positive Phase 3 study results for KEYTRUDA in combination with chemotherapy for high-risk, early-stage ER-positive, HER2-negative breast cancer, showing a significant improvement in pCR rate compared to neoadjuvant placebo plus chemotherapy. The trial will continue to evaluate the other primary endpoint of event-free survival. Safety profile consistent with previous studies. Results to be presented at upcoming medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial
-
News
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Rhea-AI Summary
Merck (NYSE: MRK) Announces Positive Phase 3 Results for V116 Pneumococcal Vaccine, Demonstrating Strong Immune Responses in Adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial
News
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Rhea-AI Summary
Merck and Moderna initiate Phase 3 trial for V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment for melanoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
clinical trial
-
News
Merck Announces Fourth-Quarter 2023 Dividend
Rhea-AI Summary
Merck announces quarterly dividend of $0.73 per share for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
dividends
-
News
Merck is Safeguarding the Environment Through Green Chemistry
Rhea-AI Summary
Merck & Co., Inc. (MRK) announces multiple awards for their innovative green chemistry solutions, highlighting their commitment to environmental sustainability and responsible operations. The awards include the 2023 Peter J. Dunn Award and the 2022 Green Chemistry Award, recognizing the development of sustainable manufacturing processes and the use of natural substances to reduce hazardous waste. Merck has also received the Green Chemistry Challenge Award for the sixth consecutive year, showcasing their dedication to environmental stewardship and product innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
News
Merck Receives Positive European Union CHMP Opinion for Gefapixant
Rhea-AI Summary
Merck (MRK) announced that the CHMP of the EMA has recommended the approval of gefapixant, an oral treatment for adults with refractory or unexplained chronic cough. This recommendation will be reviewed by the EC for marketing authorization in the EU, with a final decision expected later this year. The positive opinion is based on results from the COUGH-1 and COUGH-2 clinical trials, demonstrating a reduction in 24-hour cough frequency in adults treated with gefapixant 45 mg twice daily versus placebo at 12 weeks (COUGH-1) and 24 weeks (COUGH-2).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
News
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
Rhea-AI Summary
Merck (MRK) receives positive CHMP opinion for KEYTRUDA in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in the EU. The recommendation is based on positive progression-free survival results from the Phase 3 KEYNOTE-811 trial, showing a statistically significant improvement in PFS and ORR compared to trastuzumab and chemotherapy alone in patients whose tumors expressed PD-L1 (CPS ≥1).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
News
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Rhea-AI Summary
MRK: Merck Announces Positive Results for KEYTRUDA in Phase 3 Trial for Locally Advanced Cervical Cancer Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
earnings
Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#25 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1267 Ranked by Dividends

MRK Stock Data

322.99B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
KENILWORTH

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.